FDA stalls Eisai—and its new partner Merck—in quest to widen cancer drug Lenvima's reach

The FDA now expects to make a decision on Lenvima in first-line liver cancer by the end of August. (Eisai)

Merck & Co. was expecting big things from Eisai’s Lenvima in March, when it agreed to shell out up to $5.8 billion on half of the liver cancer drug’s sales. But in the first expansion bid since that deal, Lenvima has hit a snag.

The FDA pushed back its decision on Lenvima as a treatment for previously untreated liver cancer patients, the companies said Friday, noting only that the agency needed “additional time for review of the application.” The partners now expect a verdict by Aug. 24, three months after the original decision deadline.

“Eisai, as the marketing authorization holder, is working closely with the FDA to support the continued review of this application,” they added in a statement.


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

The delay marks a reprieve for Bayer, whose Nexavar dominates the first-line liver cancer field. Last year, Eisai unveiled data showing that Lenvima had actually topped the stalwart in a head-to-head showdown—if only slightly—by posting a 13.6-month overall survival benefit compared with Nexavar’s 12.3.

That showing surely factored into Merck’s recent decision to drop a pretty penny on a Lenvima partnership with Eisai. The New Jersey drugmaker handed over $300 million upfront and up to $650 million more for certain rights, along with $450 million in R&D reimbursement. It also pledged $385 million more if the partners nail their clinical and regulatory targets and earmarked $3.97 billion more for Eisai to pocket if the pair hits their sales marks.

RELATED: In another blockbuster cancer deal, Merck lays out up to $5.8B for half of Eisai's Lenvima

Not all of that is riding on success in liver cancer, though. For one, Merck and Eisai in January grabbed the FDA’s breakthrough therapy designation for a combo of Lenvima and Merck immuno-oncology star Keytruda in patients with advanced or metastatic kidney cancer.

As part of the partnership, the companies revealed plans to take the pairing into a slew of new clinical trials, testing it in indications across endometrial cancer, non-small cell lung cancer, head and neck cancer, bladder cancer, melanoma and more.

Suggested Articles

After early threats, the FDA finished reviewing the company's response to a citation for data manipulation and decided not to take any further action.

China is quickly getting back up to speed with API production but reports freight bottlenecks are slowing deliveries.

Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.